FrancophonIA/ELRC3.0 huggingface dataset:
English: Significant weight gain may adversely affect your health.
Slovenian: Preveliko povečanje telesne mase ima lahko neželene učinke na vaše zdravje, zato mora vaš zdravnik redno spremljati vašo telesno maso.
English: For patients with mild renal impairment (creatinine clearance ≥ 50 to < 80 mL/min), the recommended initial dose is 3 mg once daily.
Slovenian: Pri bolnikih z blago okvaro ledvic (očistek kreatinina ≥ 50 do < 80 ml/min) je priporočeni začetni odmerek zdravila INVEGA 3 mg enkrat na dan. Odmerek se lahko poveča na 6 mg enkrat na dan glede na klinični odziv in prenosljivost zdravila.
English: Schizophrenia: The recommended starting dose of INVEGA for the treatment of schizophrenia in adolescents 15 years and older is 3 mg once daily, administered in the morning.
Slovenian: Shizofrenija: Pri zdravljenju shizofrenije pri mladostnikih, starih 15 let in več, je priporočeni začetni odmerek zdravila INVEGA 3 mg enkrat na dan zjutraj.
English: Each INVEGA 9 mg prolonged-release tablet contains 9 mg of paliperidone.
Slovenian: Ena INVEGA 9 mg tableta s podaljšanim sproščanjem vsebuje 9 mg paliperidona.
English: • restlessness
Slovenian: • nemir
English: General disorders pyrexia, asthenia, fatigue face oedema, oedema e, chills, body temperature increased, gait abnormal, thirst, chest pain, chest discomfort, malaise hypothermia c, body temperature decreased c, drug withdrawal syndrome induration
Slovenian: Splošne težave in spremembe na mestu aplikacije pireksija, astenija, utrujenost edem obraza e, mrzlica, zvišana telesna temperatura, nenormalna drža, žeja, bolečina v prsih, nelagodje v prsih, splošno slabo počutje hipotermija c, znižana telesna temperatura c,
English: The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.
Slovenian: Bolnika naj torej ne skrbi, če v blatu občasno opazi nekaj podobnega tableti.
English: EU/1/07/395/001 - 005 EU/1/07/395/021 - 025 EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067
Slovenian: EU/1/07/395/021 - 025 EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067
English: The active ingredient, paliperidone, dissolves once swallowed and the tablet shell is passed out of the body as waste.
Slovenian: Ovojnica tablete in netopne sestavine iz jedra tablete se izločijo iz telesa.
English: Cardiac disorders atrioventricular block, conduction disorder, electrocardiogra m QT prolonged, bradycardia,
Slovenian: Srčne bolezni atrioventrikularni blok, motnje prevajanja, podaljšan interval QT na elektrokardiogramu, bradikardija, tahikardija sinusna aritmija, nenormalen elektrokardiogram, palpitacije atrijska fibrilacija, ortostatski posturalni tahikardni sindrom
English: Weight gain Significant weight gain has been reported with INVEGA use.
Slovenian: Pri uporabi zdravila INVEGA so poročali o pomembnem povečanju telesne mase.
English: Each INVEGA 12 mg prolonged-release tablet contains 12 mg of paliperidone.
Slovenian: Ena INVEGA 12 mg tableta s podaljšanim sproščanjem vsebuje 12 mg paliperidona.
English: Each prolonged-release tablet contains 9 mg of paliperidone.
Slovenian: Ena tableta s podaljšanim sproščanjem vsebuje 9 mg paliperidona.
English: Hypromellose Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (red) (E172) Carnauba wax
Slovenian: Obloga hipromeloza titanov dioksid (E171) makrogol 400 rdeči železov oksid (E172) karnauba vosek
English: Psychiatric disorders: sleep-related eating disorder Nervous system disorders: cerebrovascular disorder Eye disorders: floppy iris syndrome (intraoperative) Respiratory, thoracic and mediastinal disorders: rales
Slovenian: Očesne bolezni: sindrom ohlapne šarenice (medoperativni) Bolezni dihal, prsnega koša in mediastinalnega prostora: piskanje v pljučih
English: Each INVEGA 6 mg prolonged-release tablet contains 6 mg of paliperidone.
Slovenian: Ena INVEGA 6 mg tableta s podaljšanim sproščanjem vsebuje 6 mg paliperidona.
English: 98 prolonged-release tablets - EU/1/07/395/030 - WHITE
Slovenian: 14 prolonged-release tablets - EU/1/07/395/073
English: Each INVEGA 3 mg prolonged-release tablet contains 3 mg of paliperidone.
Slovenian: Ena INVEGA 3 mg tableta s podaljšanim sproščanjem vsebuje 3 mg paliperidona.
English: The recommended dose of INVEGA for the treatment of schizoaffective disorder in adults is 6 mg once daily, administered in the morning.
Slovenian: Pri zdravljenju shizoafektivne motnje pri odraslih je priporočeni odmerek zdravila INVEGA 6 mg enkrat na dan zjutraj.
English: • blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
Slovenian: Krvni strdki lahko potujejo s krvjo v pljuča in povzročijo bolečine v prsih in težko dihanje.
English: Each prolonged-release tablet contains 3 mg of paliperidone.
Slovenian: Ena tableta s podaljšanim sproščanjem vsebuje 3 mg paliperidona.
English: • hives (or “nettle rash”), hair loss, eczema, acne
Slovenian: • izpuščaji (koprivnica), izpadanje las, ekcem, akne
English: Each prolonged-release tablet contains 12 mg of paliperidone.
Slovenian: Ena tableta s podaljšanim sproščanjem vsebuje 12 mg paliperidona.
English: 30 prolonged-release tablets - EU/1/07/395/057 350 prolonged-release tablets - EU/1/07/395/058
Slovenian: 30 tablet s podaljšanim sproščanjem - EU/1/07/395/057 350 tablet s podaljšanim sproščanjem - EU/1/07/395/058
English: Each prolonged-release tablet contains 6 mg of paliperidone.
Slovenian: Ena tableta s podaljšanim sproščanjem vsebuje 6 mg paliperidona.
English: Events of leucopenia, neutropenia, and agranulocytosis have been reported with antipsychotic agents, including INVEGA.
Slovenian: Pri uporabi antipsihotikov, vključno z zdravilom INVEGA, so poročali o primerih levkopenije, nevtropenije in agranulocitoze.
English: Sodium content
Slovenian: ŠKATLA ZA VSEBNIK
English: Talk to your doctor, pharmacist or nurse before taking INVEGA.
Slovenian: Pred začetkom jemanja zdravila INVEGA se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
English: 30 prolonged-release tablets - EU/1/07/395/063 350 prolonged-release tablets - EU/1/07/395/064
Slovenian: 30 tablet s podaljšanim sproščanjem - EU/1/07/395/063 350 tablet s podaljšanim sproščanjem - EU/1/07/395/064
English: • experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty breathing.
Slovenian: • opazite krvne strdke v venah, največkrat v venah nog (simptomi so oteklina, bolečina in rdečina noge).
English: 30 prolonged-release tablets - EU/1/07/395/061 350 prolonged-release tablets - EU/1/07/395/062
Slovenian: 30 tablet s podaljšanim sproščanjem - EU/1/07/395/061 350 tablet s podaljšanim sproščanjem - EU/1/07/395/062
English: Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (yellow) (E172) Carnauba wax
Slovenian: Obloga hipromeloza titanov dioksid (E171) makrogol 400 rumeni železov oksid (E172) karnauba vosek
English: - Bottles: The tablets are supplied in a plastic bottle with a child-resistant plastic cap. Each bottle contains either 30 tablets or 350 tablets.
Slovenian: En vsebnik vsebuje 30 tablet ali 350 tablet.
English: Consideration should be given to the prolonged-release nature of the product when assessing treatment needs and recovery.
Slovenian: Pri oceni potrebe po zdravljenju in bolnikovega okrevanja upoštevajte, da se zdravilo sprošča dlje časa.
English: 30 prolonged-release tablets - EU/1/07/395/059 350 prolonged-release tablets - EU/1/07/395/060
Slovenian: 30 tablet s podaljšanim sproščanjem - EU/1/07/395/059 350 tablet s podaljšanim sproščanjem - EU/1/07/395/060
English: Caution is recommended if paliperidone is used in such patients.
Slovenian: Kadar pri njih uporabljate paliperidon, je priporočljiva previdnost.
English: Excipients
Slovenian: Prolaktin
English: Current or past use of medicines with alpha 1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery.
Slovenian: Očesni kirurg mora biti pred operacijo seznanjen, če bolnik jemlje oziroma je jemal zdravila z antagonističnim učinkom na receptorje alfa-1a.
English: The recommended dose of INVEGA for the treatment of schizophrenia in adults is 6 mg once daily, administered in the morning.
Slovenian: Pri zdravljenju shizofrenije pri odraslih je priporočeni odmerek zdravila INVEGA 6 mg enkrat na dan zjutraj.
English: 14 prolonged-release tablets - EU/1/07/395/070 28 prolonged-release tablets - EU/1/07/395/045 49 prolonged-release tablets - EU/1/07/395/046 56 prolonged-release tablets - EU/1/07/395/047 98 prolonged-release tablets - EU/1/07/395/048
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/070 28 tablet s podaljšanim sproščanjem - EU/1/07/395/045 49 tablet s podaljšanim sproščanjem - EU/1/07/395/046 56 tablet s podaljšanim sproščanjem - EU/1/07/395/047 98 tablet s podaljšanim sproščanjem - EU/1/07/395/048
English: Trilayer capsule-shaped white tablets of 11 mm in length and 5 mm in diameter printed with “PAL 3” Trilayer capsule-shaped beige tablets of 11 mm in length and 5 mm in diameter printed with “PAL 6” Trilayer capsule-shaped pink tablets of 11 mm in length and 5 mm in diameter printed with “PAL 9” Trilayer capsule-shaped yellow tablets of 11 mm in length and 5 mm in diameter printed with “PAL 12”
Slovenian: Triplastne rjavkaste tablete v obliki kapsul, dolžine 11 mm, premera 5 mm, z napisom “PAL 6”.
English: Butyl hydroxytoluene (E321) Ferric Oxide (Yellow) (E172) (3, 12 mg tablet only) Polyethylene Oxide 7000K Ferric Oxide (Red) (E172)
Slovenian: natrijev klorid povidon (K29-32) stearinska kislina butilhidroksitoluen (E321) rumeni železov oksid (E172) (samo v 3 mg in 12 mg tabletah) polietilenoksid 7000K rdeči železov oksid (E172) hidroksietilceluloza makrogol 3350 celulozni acetat črni železov oksid (E172) (samo v 9 mg tabletah)
English: 14 prolonged-release tablets - EU/1/07/395/067 28 prolonged-release tablets - EU/1/07/395/041 49 prolonged-release tablets - EU/1/07/395/042 56 prolonged-release tablets - EU/1/07/395/043 98 prolonged-release tablets - EU/1/07/395/044
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/067 28 tablet s podaljšanim sproščanjem - EU/1/07/395/041 49 tablet s podaljšanim sproščanjem - EU/1/07/395/042 56 tablet s podaljšanim sproščanjem - EU/1/07/395/043 98 tablet s podaljšanim sproščanjem - EU/1/07/395/044
English: INVEGA should not be used while breast feeding.
Slovenian: Med dojenjem matere ne smejo jemati zdravila INVEGA.
English: INVEGA contains sodium
Slovenian: Vsebujejo laktozo.
English: 14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/076 28 tablet s podaljšanim sproščanjem - EU/1/07/395/053 49 tablet s podaljšanim sproščanjem - EU/1/07/395/054 56 tablet s podaljšanim sproščanjem - EU/1/07/395/055 98 tablet s podaljšanim sproščanjem - EU/1/07/395/056
English: Hepatobiliary disorders transaminases increased gamma-glutamyltran sferase increased, hepatic enzyme increased jaundice
Slovenian: Bolezni jeter, žolčnika in žolčevodov zvišana koncentracija transaminaz zvišana koncentracija gamaglutamil transferaze, zvišane koncentracije jetrnih encimov zlatenica
English: 14 prolonged-release tablets - EU/1/07/395/074 - CLEAR 28 prolonged-release tablets - EU/1/07/395/016 - CLEAR 30 prolonged-release tablets - EU/1/07/395/017 - CLEAR 49 prolonged-release tablets - EU/1/07/395/018 - CLEAR 56 prolonged-release tablets - EU/1/07/395/019 - CLEAR 98 prolonged-release tablets - EU/1/07/395/020 - CLEAR
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/074 - PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/016 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/017 - PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/018 - PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/019 - PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/020 - PROZOREN PRETISNI OMOT
English: Dosage reduction for this medicine should be considered when this medicine is co-administered with valproate.
Slovenian: Ob sočasni uporabi z valproatom bo zdravnik pretehtal možnost zmanjšanja odmerka tega zdravila .
English: 14 prolonged-release tablets - EU/1/07/395/071 - CLEAR 28 prolonged-release tablets - EU/1/07/395/011 - CLEAR 30 prolonged-release tablets - EU/1/07/395/012 - CLEAR 49 prolonged-release tablets - EU/1/07/395/013 - CLEAR 56 prolonged-release tablets - EU/1/07/395/014 - CLEAR 98 prolonged-release tablets - EU/1/07/395/015 - CLEAR
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/071 - PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/011 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/012 - PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/013 - PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/014 - PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/015 - PROZOREN PRETISNI OMOT
English: conjunctivitis, dry eye glaucoma, eye movement disorder c,
Slovenian: Očesne bolezni zamegljen vid fotofobija, konjuktivitis, suhe oči glavkom, motnja premikanja oči c,
English: • inflammation of the pancreas
Slovenian: • vnetje trebušne slinavke
English: 14 prolonged-release tablets - EU/1/07/395/066 - WHITE 28 prolonged-release tablets - EU/1/07/395/021 - WHITE 30 prolonged-release tablets - EU/1/07/395/022 - WHITE 49 prolonged-release tablets - EU/1/07/395/023 - WHITE 56 prolonged-release tablets - EU/1/07/395/024 - WHITE 98 prolonged-release tablets - EU/1/07/395/025 - WHITE
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/066 - BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/021 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/022 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/023 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/024 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/025 - BEL PRETISNI OMOT
English: 14 prolonged-release tablets - EU/1/07/395/072 - WHITE 28 prolonged-release tablets - EU/1/07/395/031 - WHITE 30 prolonged-release tablets - EU/1/07/395/032 - WHITE 49 prolonged-release tablets - EU/1/07/395/033 - WHITE 56 prolonged-release tablets - EU/1/07/395/034 - WHITE 98 prolonged-release tablets - EU/1/07/395/035 - WHITE
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/072 - BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/031 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/032 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/033 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/034 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/035 - BEL PRETISNI OMOT
English: 14 prolonged-release tablets - EU/1/07/395/075 - WHITE 28 prolonged-release tablets - EU/1/07/395/036 - WHITE 30 prolonged-release tablets - EU/1/07/395/037 - WHITE 49 prolonged-release tablets - EU/1/07/395/038 - WHITE 56 prolonged-release tablets - EU/1/07/395/039 - WHITE 98 prolonged-release tablets - EU/1/07/395/040 - WHITE
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/075 - BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/036 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/037 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/038 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/039 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/040 - BEL PRETISNI OMOT
English: 14 prolonged-release tablets - EU/1/07/395/065 - CLEAR 28 prolonged-release tablets - EU/1/07/395/001 - CLEAR 30 prolonged-release tablets - EU/1/07/395/002 - CLEAR 49 prolonged-release tablets - EU/1/07/395/003 - CLEAR 56 prolonged-release tablets - EU/1/07/395/004 - CLEAR 98 prolonged-release tablets - EU/1/07/395/005 - CLEAR
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/065 - PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/001 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/002 - PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/003 - PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/004 - PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/005 - PROZOREN PRETISNI OMOT
English: 14 prolonged-release tablets - EU/1/07/395/068 - CLEAR 28 prolonged-release tablets - EU/1/07/395/006 - CLEAR 30 prolonged-release tablets - EU/1/07/395/007 - CLEAR 49 prolonged-release tablets - EU/1/07/395/008 - CLEAR 56 prolonged-release tablets - EU/1/07/395/009 - CLEAR 98 prolonged-release tablets - EU/1/07/395/010 - CLEAR
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/068 - PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/006 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/007- PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/008- PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/009- PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/010- PROZOREN PRETISNI OMOT
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
Slovenian: Izgled zdravila INVEGA in vsebina pakiranja
English: 14 prolonged-release tablets - EU/1/07/395/073 28 prolonged-release tablets - EU/1/07/395/049 49 prolonged-release tablets - EU/1/07/395/050 56 prolonged-release tablets - EU/1/07/395/051 98 prolonged-release tablets - EU/1/07/395/052
Slovenian: 28 tablet s podaljšanim sproščanjem - EU/1/07/395/049 49 tablet s podaljšanim sproščanjem - EU/1/07/395/050 56 tablet s podaljšanim sproščanjem - EU/1/07/395/051 98 tablet s podaljšanim sproščanjem - EU/1/07/395/052
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Iron oxide (black) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Slovenian: Jedro polietilenoksid 200K natrijev klorid povidon (K29-32) stearinska kislina butilhidroksitoluen (E321) polietilenoksid 7000K rdeči železov oksid (E172) črni železov oksid (E172) hidroksietilceluloza makrogol 3350 celulozni acetat
English: 14 prolonged-release tablets - EU/1/07/395/069 - WHITE 28 prolonged-release tablets - EU/1/07/395/026 - WHITE 30 prolonged-release tablets - EU/1/07/395/027 - WHITE 49 prolonged-release tablets - EU/1/07/395/028 - WHITE 56 prolonged-release tablets - EU/1/07/395/029 - WHITE
Slovenian: 14 tablet s podaljšanim sproščanjem - EU/1/07/395/069- BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/026- BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/027 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/028- BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/029 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/030 - BEL PRETISNI OMOT
English: Responder, n (%) Non-responder, n (%) P value (vs Placebo) R076477-SCH-305
Slovenian: Razlika med srednjimi vrednostmi LS (SE) R076477-SCH-305
English: Responder, n (%) Non-responder, n (%) P value (vs Placebo) R076477-SCH-304
Slovenian: Razlika med srednjimi vrednostmi LS (SE) R076477-SCH-304
English: 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised by the liver.
Slovenian: En teden po zaužitju enkratnega peroralnega odmerka 1 mg radioaktivno označenega paliperidona-14C s takojšnjim sproščanjem se je 59% odmerka izločilo v nespremenjeni obliki s sečem, kar pomeni, da v jetrih ne pride do obsežne presnove paliperidona.
English: • blurry vision
Slovenian: • omotica
English: Butyl hydroxytoluene (E321) Ferric oxide (yellow) (E172) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Slovenian: Jedro polietilenoksid 200K natrijev klorid povidon (K29-32) stearinska kislina butilhidroksitoluen (E321) rumeni železov oksid (E172) polietilenoksid 7000K rdeči železov oksid (E172) hidroksietilceluloza makrogol 3350 celulozni acetat
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Slovenian: Jedro polietilenoksid 200K natrijev klorid povidon (K29-32) stearinska kislina butilhidroksitoluen (E321) polietilenoksid 7000K rdeči železov oksid (E172) hidroksietilceluloza makrogol 3350 celulozni acetat
English: Adverse Drug Reaction Frequency
Slovenian: Prehod na drugo antipsihotično zdravilo
English: convulsion e,
Slovenian: Biotranformacija in izločanje
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States
Slovenian: Dodatek I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
English: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Romania
Slovenian: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Romunija
English: Heinzelova 62a 10 000 Zagreb Croatia
Slovenian: Heinzelova 62a 10 000 Zagreb Hrvaška
English: Via Vitorchiano 151 00189 Roma Italy
Slovenian: Via Vitorchiano 151 00189 Roma Italija
English: 34 avenue Léonard de Vinci 92400 Courbevoie France
Slovenian: 34 avenue Léonard de Vinci 92400 Courbevoie Francija
English: Šmartinska cesta 140 1000 Ljubljana Slovenia
Slovenian: Šmartinska cesta 140 1000 Ljubljana Slovenija
English: 174 56 Alimos Greece
Slovenian: 174 56 Alimos Grčija
English: Red Oak North South County Business Park Leopardstown
Slovenian: Red Oak North South County Business Park
English: 85540 Haar
Slovenian: 85540 Haar Nemčija
English: Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Italy
Slovenian: Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Italija
English: Edifício Vasco da Gama 2770-192 Paço de Arcos Portugal
Slovenian: Quinta da Fonte, 19 Edifício Vasco da Gama 2770-192 Paço de Arcos Portugalska
English: 0.05% w/w Mometasone furoate (monohydrate) calculated on the anhydrous basis
Slovenian: 0,05 % w/w mometazonfuroat, preračunano na podlagi brezvodne osnovne učinkovine
English: Belgium MSD Belgium BVBA/SPRL Clos du Lynx 5
Slovenian: MSD Belgium BVBA/SPRL Clos du Lynx 5
English: Luxembourg MSD Belgium BVBA/SPRL Clos du Lynx 5
Slovenian: Luksemburg MSD Belgium BVBA/SPRL Clos du Lynx 5
English: 2031 BN Haarlem P.O.
Slovenian: 2031 BN Haarlem P.O. Box 581
English: Nasonex aquosumNasenspray
Slovenian: Nasonex aquosum - Nasenspray nazalna uporaba
English: Germany MSD SHARP & DOHME GMBH
Slovenian: MSD SHARP & DOHME GMBH
English: Denmark Merck Sharp & Dohme BV Waarderweg 39
Slovenian: Merck Sharp & Dohme BV Waarderweg 39
English: Merck Sharp & Dohme Ltd Hertford Road Hoddesdon
Slovenian: Velika Britanija Merck Sharp & Dohme Ltd Hertford Road
English: In the MRP the United Kingdom is the Reference Member State and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Iceland, Luxembourg, The Netherlands, Portugal, Spain and Sweden are Concerned Member States.
Slovenian: V postopku medsebojnega priznavanja je bilo Združeno kraljestvo referenčna država članica, medtem ko so bile Avstrija, Belgija, Danska, Finska, Francija, Grčija, Nemčija, Italija, Irska, Islandija, Luksemburg, Nizozemska, Portugalska, Španija in Švedska zadevne države članice.
English: Germany atmadisc
Slovenian: Nemčija atmadisc
English: 15232 Halandri, Athens Greece
Slovenian: 15232 Halandri, Athens, Grčija
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each single actuation of Seretide provides:
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena sprožitev Seretida zagotavlja: